Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 35560054.
- Also identified by DOI 10.1001/jamanetworkopen.2022.12073 and PMC identifier 9107029.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This cohort study examines neutralizing antibodies against the SARS-CoV-2 Omicron variant (BA.1) after the second and third doses of the BNT162b2 mRNA vaccine among Danish adults.
Medical subject headings
- COVID-19
- SARS-CoV-2